Molecular Pathology of Pancreatic Ductal Adenocarcinoma
Cancers · 02.11.2025 · 17 (21) · 3549
DOI: 10.3390/cancers17213549 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 02.11.2025. Verfasst von Akram Shalaby und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 104 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer that frequently presents at an advanced stage with limited effective treatment options and a dismal prognosis. It is a highly heterogenous disease driven by various genetic and epigenetic alterations. Recent advances in sequencing modalities have significantly improved our understanding of the genetics of PDAC, which could lead to promising and novel therapeutic strategies. In this review, we summarize the most up-to-date literature on the molecular landscape of PDAC and its precursor lesions, as well as recent advances in targeted therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pathology, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.
ORCID-Profile: Akram Shalaby, Navid Sadri, Yue Xue
Zitieren
APA
Shalaby, A., Sadri, N., & Xue, Y. (2025). Molecular Pathology of Pancreatic Ductal Adenocarcinoma. Cancers, 17(21), 3549. https://doi.org/10.3390/cancers17213549
Vancouver
Shalaby A, Sadri N, Xue Y. Molecular Pathology of Pancreatic Ductal Adenocarcinoma. Cancers. 2025;17(21):3549. doi:10.3390/cancers17213549
BibTeX
@article{Shalaby2025,
author = {Shalaby, Akram and Sadri, Navid and Xue, Yue},
title = {Molecular Pathology of Pancreatic Ductal Adenocarcinoma},
journal = {Cancers},
year = {2025},
volume = {17},
number = {21},
pages = {3549},
doi = {10.3390/cancers17213549}
}
EUVIMED